FTH — Faeth Therapeutics, Share News
0.000.00%
Last trade - 00:00- $459.38m
- $256.60m
Brief: Sensei Biotherapeutics Doses First Patient In Phase 1B/2 Trial Of Piktor In Hr+/Her2- Advanced Breast Cancer
Brief: Sensei Biotherapeutics Reports Full Year 2025 Financial Results And Provides Corporate Update
Brief: Sensei Biotherapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(C)(4)
Brief: Sensei Biotherapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(C)(4)
NASDAQ RESUMED AT 10:01 AM
NASDAQ TRADE HALT VOLATILITY TRADING PAUSE AT 09:49 AM
NASDAQ RESUMED AT 10:03 AM
NASDAQ TRADE HALT VOLATILITY TRADING PAUSE AT 09:53 AM
NASDAQ RESUMED AT 09:44 AM
NASDAQ TRADE HALT VOLATILITY TRADING PAUSE AT 09:38 AM
NASDAQ RESUMED AT 09:00 AM
NASDAQ TRADE HALT HALT NEWS PENDING AT 07:55 AM
Brief: Egle Therapeutics Appoints John Celebi As Chief Executive Officer
Sensei Biotherapeutics Q3 loss narrows; reduces workforce by 65%
U.S. STOCKS ON THE MOVE-Fiserv, CMS Energy, Moderna
Sensei falls as it scraps cancer drug development, plans to sell itself
Sensei Biotherapeutics Inc reports results for the quarter ended June 30 - Earnings Summary
Sensei Biotherapeutics Inc expected to post a loss of $5.60 a share - Earnings Preview
Brief: Sensei Biotherapeutics Announces 1-For-20 Reverse Stock Split